Overview

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Status:
Completed

Trial end date:
2017-10-31

Target enrollment:

Participant gender:

Summary

A single arm, open-label, multi-center phase IV clinical trial for patients with metastatic renal cell carcinoma, who have progressed on or after the first VEGF-targeted therapy.

Phase:

Phase 4

Details

Lead Sponsor:

iOMEDICO AG

Collaborator:

Novartis

Treatments:

Everolimus
Sirolimus